400-0512-686

News

News
Location:Home >News >News

April 24, 2014, Lumigenex announced today

Poptime:2014-10-19 Page View:1579

April 24, 2014, Lumigenex announced today that it had received certificates of registration from CFDA for four POCT immunoassay kits: Creatine Kinase (CK-MB) quantitative detection kit (time-resolved fluorescence immunochromatographic assay); Myoglobin (MYO) quantitative detection kit ((time-resolved fluorescence immunochromatographic assay); cardiac troponin I (cTnI) quantitative detection kit ((time-resolved fluorescence immunochromatographic assay); N-terminal brain natriuretic peptide (NT-proBNP) quantitative detection kit ((time-resolved fluorescence immunochromatographic assay).
Earlier
April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.